In this study, A549 cells with strong malignancy was used as the model cell line, and focused on exploring whether a survivin mutant protein with stronger anti-cancer activity could be obtained by adding one or two other mutation sites based on TmSm34. This evidence concerns the gene BIRC5 and cancer.